Immunocore Reports Director/Officer Changes
Ticker: IMCR · Form: 8-K · Filed: Nov 28, 2025 · CIK: 1671927
| Field | Detail |
|---|---|
| Company | Immunocore Holdings PLC (IMCR) |
| Form Type | 8-K |
| Filed Date | Nov 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: IMCR
TL;DR
Immunocore filed an 8-K for director/officer changes on Nov 26.
AI Summary
Immunocore Holdings plc filed an 8-K on November 28, 2025, reporting changes as of November 26, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. Specific details regarding the individuals involved, their roles, and the nature of the changes were not provided in the excerpt.
Why It Matters
Changes in a company's board of directors or executive officers can signal shifts in strategy, governance, or operational focus.
Risk Assessment
Risk Level: low — This filing reports routine corporate governance changes and does not indicate immediate financial or operational distress.
Key Players & Entities
- Immunocore Holdings plc (company) — Registrant
- November 26, 2025 (date) — Date of earliest event reported
- November 28, 2025 (date) — Date of report
FAQ
What specific changes were made regarding directors or officers?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific individuals and their roles are not detailed in the provided excerpt.
Were there any changes to compensatory arrangements for officers?
Yes, the filing explicitly lists 'Compensatory Arrangements of Certain Officers' as an item of information, though specifics are not in the excerpt.
What is the effective date of the reported changes?
The earliest event reported is dated November 26, 2025.
What is the company's primary business sector?
Immunocore Holdings plc is in the 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' sector, SIC code 2836.
When was Immunocore Holdings plc incorporated?
The company was incorporated in England and Wales.
Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-11-28 07:01:00
Filing Documents
- ef20060115_8k.htm (8-K) — 31KB
- 0001140361-25-043600.txt ( ) — 197KB
- imcr-20251126.xsd (EX-101.SCH) — 5KB
- imcr-20251126_def.xml (EX-101.DEF) — 17KB
- imcr-20251126_lab.xml (EX-101.LAB) — 27KB
- imcr-20251126_pre.xml (EX-101.PRE) — 20KB
- ef20060115_8k_htm.xml (XML) — 7KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Ranjeev Krishana Resignation On November 26, 2025, Ranjeev Krishana notified the board of directors (the "Board") of Immunocore Holdings plc (the "Company") of his decision to resign as a member of the Board and a member of the Remuneration Committee of the Board, effective immediately. Mr. Krishana's decision to resign was not the result of any disagreement between Mr. Krishana and the Company, management of the Company, or any other member of the Board on any matter relating to the Company's operations, policies, or practices. Tina St. Leger Resignation On November 26, 2025, Tina St. Leger notified the Company of her decision to resign as Chief Human Resources Officer of the Company, effective as of May 26, 2026, in order to pursue another opportunity. Ms. St. Leger's decision to resign was not the result of any disagreement between Ms. St. Leger and the Company or any matter relating to the Company's operations, policies, or practices. The Company has begun conducting a formal search for her replacement.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNOCORE HOLDINGS PLC Dated: November 28, 2025 By: /s/ Bahija Jallal, Ph.D. Name: Bahija Jallal, Ph.D. Title: Chief Executive Officer